// App-Quantinova.ai

: Efficacy of Lanadelumab in Hereditary Angioedema Patients With and Without Prior Use of Long-Term Prophylaxis: Final Results From the HELP Open-Label Extension Study

Researchers

Presenter

  • Kim Paes

Principal Investigators

  • Jonathan Bernstein

  • Hilary Longhurst

  • Emel Aygoren-Pursun

  • Hong Ren

  • Timothy Craig

Medical Centers

  • Takeda Pharmaceutical Company Limited, Boston, USA

  • Department of Internal Medicine, Division of Immunology, University of Cincinnati College of Medicine, Bernstein Allergy Group and Bernstein Clinical Research Center, Cincinnati, OH, USA

  • Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, and University College London Hospitals, London, UK

  • Department for Children and Adolescents, Angioedema Centre, University Hospital Frankfurt, Goethe University, Frankfurt, Germany

  • Cytel, Inc, Cambridge, MA

  • Department of Medicine, Pediatrics and Graduate Studies, Penn State University Hershey Medical Center, Hershey, PA, USA

Locations

  • United States

  • United Kingdom

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

Disease

  • Hereditary angioedema

Biomarkers

  • N/A

Drug/Treatment

  • DX2930

Outcome

  • N/A

Study Design

  • Open Label

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved